Dare Bioscience Files Proxy Materials

Ticker: DARE · Form: DEFA14A · Filed: Jun 12, 2025 · CIK: 1401914

Sentiment: neutral

Topics: proxy-statement, shareholder-materials, corporate-governance

TL;DR

Dare Bioscience dropped proxy docs, shareholders need to pay attention.

AI Summary

Dare Bioscience, Inc. filed a Definitive Additional Materials (DEFA14A) on June 12, 2025. This filing relates to materials provided to shareholders, likely concerning upcoming corporate actions or proposals. The company, previously known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc., is incorporated in Delaware and headquartered in San Diego, California.

Why It Matters

This filing indicates that Dare Bioscience is engaging with its shareholders on important corporate matters, which could impact the company's future direction and shareholder value.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement, not indicating immediate financial distress or significant operational changes.

Key Players & Entities

FAQ

What is the purpose of a DEFA14A filing?

A DEFA14A filing, or Definitive Additional Materials, is used to provide shareholders with information related to proxy solicitations, typically for annual or special meetings where shareholders will vote on corporate matters.

When was this filing made by Dare Bioscience, Inc.?

The filing was made on June 12, 2025.

What were Dare Bioscience, Inc.'s previous names?

Dare Bioscience, Inc. was formerly known as Cerulean Pharma Inc. and Tempo Pharmaceuticals Inc.

Where is Dare Bioscience, Inc. headquartered?

Dare Bioscience, Inc. is headquartered in San Diego, California.

What is the Standard Industrial Classification (SIC) code for Dare Bioscience, Inc.?

The SIC code for Dare Bioscience, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Details

This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 12, 2025 regarding Dare Bioscience, Inc. (DARE).

View full filing on EDGAR

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing